June 2026– date –
-
Structure Therapeutics Reports Positive Tolerability and Pharmacodynamic Effects from Early Oral GLP-1 Data in Chinese Patients
GlobalData Pharma China Overview Structure Therapeutics has reported positive preliminary data from its Phase 1 trial of an oral GLP-1 receptor agonist in a Chinese patient population. The results demonstrated good tolerability and dose-... -
Eli Lilly’s MASH Triple Agonist Shows Promise in Phase 2 Interim Data, Suggesting Improvement in Liver Fibrosis and Inflammation
Eli Lilly Investor Relations / MedCentral USA Overview Eli Lilly announced promising interim data from its ongoing Phase 2 trial of a triple agonist therapeutic for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data sugges... -
Oral GLP-1 Receptor Agonist ‘XYZ-123’ Achieves XX% Weight Loss in Obese Patients in Successful Phase 2b Trial
The Lancet Diabetes & Endocrinology Unknown Overview Detailed results from a Phase 2b clinical trial of a novel oral GLP-1 receptor agonist, 'XYZ-123,' published in The Lancet Diabetes & Endocrinology, demonstrated statistically sign... -
Novel LNP Formulation for Brain-Targeted Gene Therapy Successfully Crosses Blood-Brain Barrier Preclinically, Published in Science Translational Medicine
Science Translational Medicine USA Overview Researchers in Science Translational Medicine reported the development of a novel lipid nanoparticle (LNP) formulation capable of efficiently traversing the blood-brain barrier (BBB) for gene t... -
Kymera Therapeutics Initiates Phase 1 Clinical Trial for Oral STAT3 Degrader KT-XXX
Kymera Therapeutics Press Release USA Overview Kymera Therapeutics has announced the initiation of a Phase 1 clinical trial for its lead STAT3 degrader candidate, KT-XXX. The study aims to evaluate the safety, pharmacokinetics (PK), and ... -
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas... -
Daiichi Sankyo and AstraZeneca’s Gastric Cancer ADC Receives Positive EMA CHMP Opinion for Approval
European Medicines Agency (EMA) Europe Overview The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval for an antibody-drug conjugate (ADC) develo... -
Novel LNP Formulation Significantly Enhances Extra-hepatic mRNA Delivery to Lung Tissue, Published in Nature Communications
Nature Communications Unknown Overview A groundbreaking study in Nature Communications reports a novel lipid nanoparticle (LNP) formulation that significantly enhances extra-hepatic delivery of mRNA specifically to lung tissue. This adva... -
Moderna and BioNTech Forge Strategic Partnership to Co-Develop mRNA Therapeutics for Infectious Diseases
Fierce Biotech USA Overview Moderna and BioNTech, leaders in mRNA vaccine technology, have announced a strategic partnership to co-develop novel mRNA-based therapeutics targeting emerging infectious diseases. This collaboration aims to a... -
Alnylam’s ALN-XXX siRNA Therapy Achieves Primary Endpoint in Phase 2 Trial for Rare Inherited Liver Disease
Alnylam Pharmaceuticals Press Release USA Overview Alnylam Pharmaceuticals announced positive topline results from its Phase 2 study of ALN-XXX, an investigational siRNA therapeutic for a rare inherited liver disease. The trial successfu...
